{"entity":{"id":"cb-011","kind":"drug","name":"CB-011","aka":[],"tldr":"CB-011 is an experimental allogeneic CAR-T cell therapy from Caribou Biosciences, in phase 1 trials for relapsed or refractory multiple myeloma.","summary":"CB-011 is an allogeneic CAR-T cell therapy (CRISPR Cas12a chRDNA genome-edited) from Caribou Biosciences. An allogeneic anti-BCMA CAR-T cell therapy made with four Cas12a chRDNA edits: TRAC knockout, a humanised anti-BCMA CAR inserted into TRAC, and a B2M-HLA-E fusion inserted into B2M that knocks out endogenous B2M, meant to blunt T and NK cell rejection by the patient's immune system. Its furthest stage is phase 1, for relapsed or refractory multiple myeloma. ClinicalTrials.gov registers it in one study linked below. Company calls it its second clinical-stage program; NCT05722418 (phase 1) recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Caribou Biosciences: cariboubio.com","url":"https://www.cariboubio.com/pipeline"},{"label":"Caribou Biosciences: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT05722418"},{"label":"ClinicalTrials.gov: trials of CB-011","url":"https://clinicaltrials.gov/search?intr=CB-011"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloma-relapsed-refractory"],"sections":[],"technologies":[],"targets":["bcma"],"drugs":[],"companies":["caribou"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05722418"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"CB-011","modality":"Allogeneic CAR-T cell therapy (CRISPR Cas12a chRDNA genome-edited)","mechanism":"An allogeneic anti-BCMA CAR-T cell therapy made with four Cas12a chRDNA edits: TRAC knockout, a humanised anti-BCMA CAR inserted into TRAC, and a B2M-HLA-E fusion inserted into B2M that knocks out endogenous B2M, meant to blunt T and NK cell rejection by the patient's immune system.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cb-011/","neighbours":{"cancer":[{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"}],"company":[{"id":"caribou","kind":"company","name":"Caribou Biosciences","route":"/companies/caribou/"}],"trial":[{"id":"nct05722418","kind":"trial","name":"CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct05722418/"}]}}